NEWS
X-Body Platform Yields First Lead Compound for AMD BioWorld Today, | Monday, December 5, 2011
X-BODY BioSciences Enters Into R&D Partnership with Tanabe Research Labs to Generate Antibody Therapeutics for Autoimmune Disorders
http://www.mt-pharma.co.jp/e
About X-BODY, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. The modular leads generated by X-BODY's platform can be incorporated into V(H) domain, scFv, IgG and bispecific antibody formats. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates to block neovascularization that causes age-related macular degeneration. http://www.x-bodybiosciences.com
WALTHAM, Mass., Oct. 4, 2011 /PRNewswire/ -- X-BODY, Inc., a developer of monoclonal antibody therapeutics, today announced a partnership with Tanabe Research Laboratories U.S.A., Inc. (TRL). The companies will collaborate to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies to the identified therapeutic targets.
X-BODY has developed an extremely diverse human antibody library and screens it using the company's proprietary Protein Chain Reaction™. A unique feature of the platform is that it allows for screening against cell surface targets in their native state on live cells or purified target proteins. X-BODY's deep sequencing hit analysis identifies and characterizes rare antibodies with the desired therapeutic properties.
Under the terms of the Agreement between TRL and X-BODY, X-BODY will screen its proprietary libraries against target cells of therapeutic interest to TRL to identify tissue specific epitopes and human antibody therapeutic candidates. TRL will fund the collaboration. TRL has the option to negotiate rights to the antibodies discovered in the collaboration for further pre-clinical research, clinical development, and commercialization.
Roland Newman, Ph.D., Chief Scientific Officer of TRL, commented, "X-Body's technology represents a major step forward in the ability to rapidly generate thousands of human antibodies against functionally relevant targets. The power and versatility of X-Body's platform in generating antibodies against targets that are inaccessible by conventional techniques offers new and exciting prospects. We are looking forward to a positive and productive relationship with X-Body."
"The TRL team is focused on developing innovative biologics targeting autoimmune diseases and X-BODY is excited about collaborating with TRL to develop antibody therapeutics," said Tod Woolf, Ph.D., Chief Business Officer of X-BODY. "We are gratified to announce this third partnership since the public launch of our platform at IBC's Antibody Engineering Conference last December," added Dr. Woolf.
About TRL:
TRL is an independent subsidiary of Mitsubishi Tanabe Pharma Corporation whose role is to discover and develop potential biological drug candidates for therapy in autoimmune diseases. Currently, TRL's efforts will be directed towards antibody and antibody related research to target specific immune cells and soluble factors, as well as investigating new methods for modulating immune cell functions. TRL is establishing collaborative relationships with other companies and academic research organizations to further its goals of identifying lead preclinical compounds for further development and to consolidate its presence in immunology. http://www.trlusa.com/
About Mitsubishi Tanabe Pharma Corporation.
http://www.mt-pharma.co.jp/e
About X-BODY, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. The modular leads generated by X-BODY's platform can be incorporated into V(H) domain, scFv, IgG and bispecific antibody formats. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates to block neovascularization that causes age-related macular degeneration. http://www.x-bodybiosciences.com
Mercator Therapeutics and X-BODY BioSciences Establish Alliance to Generate Antibody Cancer Therapeutics
WALTHAM, Mass., Jan. 6, 2011 /Business Wire/ -- Mercator Therapeutics, Inc., the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration. The companies will collaborate to develop antibodies to four of Mercator's cancer targets identified using Mercator's proprietary in vivo screening technology.
Mercator discovers 'Homing Peptides' and the rapidly internalizing receptors to which they home using a unique in vivo screening process, including screening in end-stage cancer patients under strict ethical guidelines. By letting the screen define the target, Mercator identifies uniquely validated oncology targets. These targets are ideally suited for the development of monoclonal antibodies (mAbs), which can be used either as stand-alone therapeutics or as targeting moieties to selectively deliver cytotoxic agents to tumor cells. X-BODY's fully human library captures the natural antibody repertoire. Compared to synthetic libraries, fully human libraries reduce the probability of side effects due to immune responses. Protein Chain Reaction™, one of the key features of X-BODY's therapeutic platform, allows for screening against cell surface targets in their native state on live cells or purified target proteins.
Dr. Roy Lobb, Chairman&CSO of Mercator, commented, "X-BODY has identified a direct, rapid, and efficient path to fully human mAbs and mAb fragments, and we look forward to a productive collaboration employing the X-BODY therapeutic platform against our proprietary targets."
Under the terms of the Agreement between Mercator and X-BODY, X-BODY will screen its proprietary libraries against four of Mercator's cancer targets to identify human antibody therapeutic candidates. Mercator has the right to acquire rights to the antibodies discovered in the collaboration for further pre-clinical research, clinical development, and commercialization. Mercator will pay X-BODY undisclosed research funding, assignment fees, milestones, and royalties in connection with the development of products resulting from the collaboration.
"Mercator is changing the cancer treatment paradigm by developing therapeutics that selectively target receptors that are highly expressed on human tumor cells, and X-BODY is excited about collaborating with Mercator to develop these much needed cancer therapeutics," said Dr. Rick Wagner, Executive Chairman of X-BODY.
About Mercator Therapeutics, Inc.
Mercator Therapeutics is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. Mercator was founded to translate the research of Drs. Wadih Arap and Renata Pasqualini into effective cancer therapeutics. Drs. Arap and Pasqualini pioneered the use of in vivo phage display to identify peptides that are believed to selectively deliver tumor-killing payloads without damaging surrounding tissue. Targeting of drugs selectively to tumors in man has been a goal of basic and translational research for decades. The Arap-Pasqualini Lab is addressing this problem by directly injecting peptide-expressing phage libraries in vivo - most recently in end-stage cancer patients under strict ethical guidelines - and identifying a suite of peptides responsible for tumor targeting as well as the rapidly internalizing receptors to which the peptides home. Mercator has exclusive rights to translate this research into novel cancer therapeutics. Mercator is located in Waltham, Massachusetts. Contact Chris Guiffre at chris.guiffre@mercatortx.com for further information while Mercator's website is under construction.
About X-BODY BioSciences, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
Contacts:
Mercator Therapeutics, Inc.
Chris Guiffre
President&CEO
chris.guiffre@mercatortx.com
or
X-BODY Biosciences
Tod Woolf, +1-781-891-0029, Ext. 2920
Chief Business Officer
BD@x-bodybiosciences.com
WEB: www.x-bodybiosciences.com
WALTHAM, Mass., Jan. 6, 2011 /Business Wire/ -- Mercator Therapeutics, Inc., the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration. The companies will collaborate to develop antibodies to four of Mercator's cancer targets identified using Mercator's proprietary in vivo screening technology.
Mercator discovers 'Homing Peptides' and the rapidly internalizing receptors to which they home using a unique in vivo screening process, including screening in end-stage cancer patients under strict ethical guidelines. By letting the screen define the target, Mercator identifies uniquely validated oncology targets. These targets are ideally suited for the development of monoclonal antibodies (mAbs), which can be used either as stand-alone therapeutics or as targeting moieties to selectively deliver cytotoxic agents to tumor cells. X-BODY's fully human library captures the natural antibody repertoire. Compared to synthetic libraries, fully human libraries reduce the probability of side effects due to immune responses. Protein Chain Reaction™, one of the key features of X-BODY's therapeutic platform, allows for screening against cell surface targets in their native state on live cells or purified target proteins.
Dr. Roy Lobb, Chairman&CSO of Mercator, commented, "X-BODY has identified a direct, rapid, and efficient path to fully human mAbs and mAb fragments, and we look forward to a productive collaboration employing the X-BODY therapeutic platform against our proprietary targets."
Under the terms of the Agreement between Mercator and X-BODY, X-BODY will screen its proprietary libraries against four of Mercator's cancer targets to identify human antibody therapeutic candidates. Mercator has the right to acquire rights to the antibodies discovered in the collaboration for further pre-clinical research, clinical development, and commercialization. Mercator will pay X-BODY undisclosed research funding, assignment fees, milestones, and royalties in connection with the development of products resulting from the collaboration.
"Mercator is changing the cancer treatment paradigm by developing therapeutics that selectively target receptors that are highly expressed on human tumor cells, and X-BODY is excited about collaborating with Mercator to develop these much needed cancer therapeutics," said Dr. Rick Wagner, Executive Chairman of X-BODY.
About Mercator Therapeutics, Inc.
Mercator Therapeutics is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. Mercator was founded to translate the research of Drs. Wadih Arap and Renata Pasqualini into effective cancer therapeutics. Drs. Arap and Pasqualini pioneered the use of in vivo phage display to identify peptides that are believed to selectively deliver tumor-killing payloads without damaging surrounding tissue. Targeting of drugs selectively to tumors in man has been a goal of basic and translational research for decades. The Arap-Pasqualini Lab is addressing this problem by directly injecting peptide-expressing phage libraries in vivo - most recently in end-stage cancer patients under strict ethical guidelines - and identifying a suite of peptides responsible for tumor targeting as well as the rapidly internalizing receptors to which the peptides home. Mercator has exclusive rights to translate this research into novel cancer therapeutics. Mercator is located in Waltham, Massachusetts. Contact Chris Guiffre at chris.guiffre@mercatortx.com for further information while Mercator's website is under construction.
About X-BODY BioSciences, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
Contacts:
Mercator Therapeutics, Inc.
Chris Guiffre
President&CEO
chris.guiffre@mercatortx.com
or
X-BODY Biosciences
Tod Woolf, +1-781-891-0029, Ext. 2920
Chief Business Officer
BD@x-bodybiosciences.com
WEB: www.x-bodybiosciences.com
X-BODY Biosciences Launches Platform for Rapid Discovery of Human Antibody Therapeutics With Presentations at the 21st Annual IBC Antibody Engineering Conference
WALTHAM, Mass., Nov. 30, 2010 /PRNewswire/ -- X-BODY Biosciences, a developer of monoclonal antibody therapeutics, today announced the launch of its Protein Chain Reaction(TM) antibody discovery platform. The company will give its first public presentations at IBC's 21st Annual International Conference on Antibody Engineering held December 5-9th in San Diego. Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY will present a talk entitled, "Discovery and Characterization of hMAB Targeting an RTK Implicated in Metastasis by Live Cell Screening and Interrogation of Fully Human Libraries with Deep Sequencing" on Monday, December 6th at 11:00AM. Yan Chen, M.D./Ph.D., VP of Antibody Research at X-BODY will present a poster entitled, "Rapid Generation of hMABs Using a Novel Integrated Platform" at the conference.
X-BODY's fully human library captures the natural antibody repertoire. Compared to synthetic libraries, fully human libraries reduce the probability of side effects due to immune responses. The platform's Protein Chain Reaction(TM) allows for screening against cell surface targets in their native state on live cells or purified target proteins. X-BODY's platform employs the high throughput SRU BIND® protein detection system to screen for high affinity antibodies. X-BODY, in collaboration with SRU Biosystems, has validated a novel BIND® Biosensor design for use with the commercially available SRU BIND® Reader that results in a >500-fold increase in sensitivity over SRU’s previous sensor technology. The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated 384-well or 1536-well microplate format.
X-BODY's versatile Protein Chain Reaction(TM) screening system with deep sequencing of thousands of hits allows for the rapid identification of high quality leads with the following therapeutically relevant properties:
X-BODY has validated its platform by rapidly identifying and characterizing therapeutic candidates against an oncology and a metabolic target in less than three months. X-BODY's screening system can also generate the following:
Tod Woolf, Ph.D., X-BODY's Chief Business Officer, noted, "After two years of technology development, we are pleased to present our platform publicly for the first time at a premier therapeutic antibody scientific conference. We believe our platform provides a path to high quality human antibody therapeutic lead candidates against challenging target proteins."
About X-BODY Biosciences.
X-BODY Biosciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform (now owned by Adnexus, A Bristol Myers Squibb Company) and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GSK in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, MIT and CalTech. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY has employed its platform internally to identify therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
Further information regarding X-BODY BioSciences can be obtained at:
WEB: www.x-bodybiosciences.com
CONTACT: Tod Woolf, Chief Business Officer, X-BODY Biosciences, +1-781-891-0029, Ext. 2920, BD@x-bodybiosciences.com
SOURCE X-BODY BioSciences
WALTHAM, Mass., Nov. 30, 2010 /PRNewswire/ -- X-BODY Biosciences, a developer of monoclonal antibody therapeutics, today announced the launch of its Protein Chain Reaction(TM) antibody discovery platform. The company will give its first public presentations at IBC's 21st Annual International Conference on Antibody Engineering held December 5-9th in San Diego. Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY will present a talk entitled, "Discovery and Characterization of hMAB Targeting an RTK Implicated in Metastasis by Live Cell Screening and Interrogation of Fully Human Libraries with Deep Sequencing" on Monday, December 6th at 11:00AM. Yan Chen, M.D./Ph.D., VP of Antibody Research at X-BODY will present a poster entitled, "Rapid Generation of hMABs Using a Novel Integrated Platform" at the conference.
X-BODY's fully human library captures the natural antibody repertoire. Compared to synthetic libraries, fully human libraries reduce the probability of side effects due to immune responses. The platform's Protein Chain Reaction(TM) allows for screening against cell surface targets in their native state on live cells or purified target proteins. X-BODY's platform employs the high throughput SRU BIND® protein detection system to screen for high affinity antibodies. X-BODY, in collaboration with SRU Biosystems, has validated a novel BIND® Biosensor design for use with the commercially available SRU BIND® Reader that results in a >500-fold increase in sensitivity over SRU’s previous sensor technology. The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated 384-well or 1536-well microplate format.
X-BODY's versatile Protein Chain Reaction(TM) screening system with deep sequencing of thousands of hits allows for the rapid identification of high quality leads with the following therapeutically relevant properties:
- High affinity
- High selectivity
- Species cross-reactivity
- Broad epitope coverage
- Low immunogenicity
X-BODY has validated its platform by rapidly identifying and characterizing therapeutic candidates against an oncology and a metabolic target in less than three months. X-BODY's screening system can also generate the following:
- High affinity soluble VH domain binders
- "Bio-Better" follow-on hMABs
- Optimized VL pairs
- Multimeric VH binders
- Bispecific antibodies
Tod Woolf, Ph.D., X-BODY's Chief Business Officer, noted, "After two years of technology development, we are pleased to present our platform publicly for the first time at a premier therapeutic antibody scientific conference. We believe our platform provides a path to high quality human antibody therapeutic lead candidates against challenging target proteins."
About X-BODY Biosciences.
X-BODY Biosciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform (now owned by Adnexus, A Bristol Myers Squibb Company) and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GSK in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, MIT and CalTech. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY has employed its platform internally to identify therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
Further information regarding X-BODY BioSciences can be obtained at:
WEB: www.x-bodybiosciences.com
CONTACT: Tod Woolf, Chief Business Officer, X-BODY Biosciences, +1-781-891-0029, Ext. 2920, BD@x-bodybiosciences.com
SOURCE X-BODY BioSciences
X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells. The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services. This grant provides X-BODY with the maximum allowable 50% reimbursement of X-BODY's qualified investment of ~$500,000 in this project.
X-BODY's therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells. There is no selective inhibitor of this targeted pathway on the market. Targeting tumor-initiating cells via this pathway alone or with combination therapy may prevent metastasis in the treatment of non-small cell lung cancer and other solid tumors. Non-small cell lung cancer is a very common cancer with an 11-14% five-year survival rate and causes ~1.4 million yearly deaths globally.
X-BODY's pre-clinical candidates were discovered using X-BODY's proprietary platform, based on innovative screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.
About X-BODY BioSciences.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs Next Generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
Further information regarding X-BODY BioSciences can be obtained at:
WEB: www.x-bodybiosciences.com
SOURCE X-BODY BioSciences
WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells. The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services. This grant provides X-BODY with the maximum allowable 50% reimbursement of X-BODY's qualified investment of ~$500,000 in this project.
X-BODY's therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells. There is no selective inhibitor of this targeted pathway on the market. Targeting tumor-initiating cells via this pathway alone or with combination therapy may prevent metastasis in the treatment of non-small cell lung cancer and other solid tumors. Non-small cell lung cancer is a very common cancer with an 11-14% five-year survival rate and causes ~1.4 million yearly deaths globally.
X-BODY's pre-clinical candidates were discovered using X-BODY's proprietary platform, based on innovative screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.
About X-BODY BioSciences.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GlaxoSmithKline in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs Next Generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
Further information regarding X-BODY BioSciences can be obtained at:
WEB: www.x-bodybiosciences.com
SOURCE X-BODY BioSciences
X-BODY Biosciences and SRU Biosystems Announce Success in Development and Validation of a Novel
High-Throughput Label-Free Screening System for Antibody Discovery
WALTHAM, Mass. and WOBURN, Mass., July 22, 2010 --(BUSINESS WIRE)--X-BODY Biosciences and SRU Biosystems today announced a major collaborative advance in the application of the SRU BIND® label-free protein detection platform for high-throughput label-free screening of high affinity antibodies. The two companies have developed and validated a novel BIND® Biosensor design for use with the commercially available SRU BIND® Reader that results in a >200-fold increase in sensitivity over SRU’s previous sensor. The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated microplate format.
Commenting on the recent development, Dr. Yan Chen, X-BODY’s Vice President of Antibody Research, said, “For years, the therapeutic antibody community has sought a label-free, high- throughput screening platform to accelerate the drug discovery process. This improved BIND® protein detection system offers unprecedented throughput and sensitivity for antibody screening.”
The improved SRU BIND® system allows for high affinity measurements in 384 or 1536 well microplate formats for diagnostic, manufacturing QC and drug discovery applications. X-BODY Biosciences has developed a novel platform for rapidly screening fully human antibody libraries that incorporates the improved SRU BIND® Biosensor. X-BODY has validated the use of this new and improved SRU BIND® system for drug discovery by employing the technology to rapidly identify and characterize therapeutic candidates.
About X-BODY Biosciences
X-BODY Biosciences was founded in 2008 by Richard Wagner, Gordon Binder, and Brant Binder. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GSK in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY’s platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY’s versatile screening system employs NextGeneration sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. The platform is available for collaboration and is scalable to support global discovery efforts. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
About SRU Biosystems
SRU Biosystems, Inc. is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical and cellular targets. SRU is incorporating its BIND® technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics.
WALTHAM, Mass. and WOBURN, Mass., July 22, 2010 --(BUSINESS WIRE)--X-BODY Biosciences and SRU Biosystems today announced a major collaborative advance in the application of the SRU BIND® label-free protein detection platform for high-throughput label-free screening of high affinity antibodies. The two companies have developed and validated a novel BIND® Biosensor design for use with the commercially available SRU BIND® Reader that results in a >200-fold increase in sensitivity over SRU’s previous sensor. The novel biosensor allows for measurement of sub-nanomolar affinity interactions in an automated microplate format.
Commenting on the recent development, Dr. Yan Chen, X-BODY’s Vice President of Antibody Research, said, “For years, the therapeutic antibody community has sought a label-free, high- throughput screening platform to accelerate the drug discovery process. This improved BIND® protein detection system offers unprecedented throughput and sensitivity for antibody screening.”
The improved SRU BIND® system allows for high affinity measurements in 384 or 1536 well microplate formats for diagnostic, manufacturing QC and drug discovery applications. X-BODY Biosciences has developed a novel platform for rapidly screening fully human antibody libraries that incorporates the improved SRU BIND® Biosensor. X-BODY has validated the use of this new and improved SRU BIND® system for drug discovery by employing the technology to rapidly identify and characterize therapeutic candidates.
About X-BODY Biosciences
X-BODY Biosciences was founded in 2008 by Richard Wagner, Gordon Binder, and Brant Binder. Dr. Wagner previously co-developed the fibronectin domain antibody-mimetic platform at Phylos, later acquired by Bristol Myers Squibb, and the DirectSelect small molecule library screening system at Praecis Pharmaceuticals, acquired by GSK in 2007. Mr. Gordon Binder is the former CEO and Chairman of Amgen and member of the boards of the American Enterprise Institute, the Massachusetts Institute of Technology and the California Institute of Technology. Mr. Brant Binder is co-founder, COO and CFO of SRU Biosystems. X-BODY’s platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY’s versatile screening system employs NextGeneration sequencing to analyze thousands of hits in order to rapidly obtain high quality leads. The platform is available for collaboration and is scalable to support global discovery efforts. X-BODY has employed the platform internally to identify high-affinity therapeutic candidates that target metastasis (invasion and spreading) of cancer stem cells.
About SRU Biosystems
SRU Biosystems, Inc. is a life science company developing novel technologies for rapidly analyzing the interactions of large genomic, protein, peptide, antibody or small molecule compound libraries against a wide range of biochemical and cellular targets. SRU is incorporating its BIND® technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics.